

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (update) (Dec 2018)



Consultation on draft guideline – deadline for comments 5pm on 6 August 2018 email: COPDupdate@nice.org.uk

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.

We would like to hear your views on the draft recommendations presented in the guideline, and any comments you may have on the rationale and impact sections in the guideline and the evidence presented in the evidence reviews documents. We would also welcome views on the Equality Impact Assessment.

We would like to hear your views on these questions:

1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.
2. Would implementation of any of the draft recommendations have significant cost implications?
3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)
4. The guideline recommends that long term oxygen therapy should not be offered to people who continue to smoke despite being offered smoking cessation advice and treatment, and referral to a specialist stop smoking service. This is because the risks to the individual and people they live with outweigh the potential benefits of long-term oxygen therapy. Do you believe that this recommendation is appropriate? We would welcome your comments on this issue.
5. We propose to stand down recommendations 1.3.22 – 1.3.25 on antibiotics for the management of exacerbations. Instead the guideline will cross refer to the recommendations in the guideline on [antimicrobial prescribing for acute exacerbations of COPD](#). Do you agree with this proposal?

See section 3.9 of [Developing NICE guidance: how to get involved](#) for suggestions of general points to think about when commenting.

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (update) (Dec 2018)



Consultation on draft guideline – deadline for comments 5pm on 6 August 2018 email: COPDupdate@nice.org.uk

Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):	[Royal Pharmaceutical Society]
Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	[N/A]
Name of commentator person completing form:	[Yogeeta Bhupal- Professional Support Pharmacist]
Type	[office use only]

Please return to: COPDupdate@nice.org.uk

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (update) (Dec 2018)



Consultation on draft guideline – deadline for comments 5pm on 6 August 2018 email: COPDupdate@nice.org.uk

Comment number	Document [guideline, evidence review A, B, C etc., methods or other (please specify which)]	Page number Or 'general' for comments on whole document	Line number Or 'general' for comments on whole document	Comments
Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table.				
General Comments				The Royal Pharmaceutical Society is the professional body for pharmacists and pharmacy in Great Britain. As professionals in pharmaceutical care, pharmacists are well equipped to offer advice on management of chronic diseases. With an increasing number of pharmacist independent prescribers and those specialising in specific disease states such as chronic obstructive pulmonary disease (COPD), pharmacists are often directly involved in diagnosis and supporting patients to monitor their condition.
1	1.2.5	14	14	Community Pharmacists are ideally placed as the first point of contact for patients, to ask patients if they smoke and offer advice to stop smoking. They do this as part of their consultation when handing out prescriptions and when undertaking medication reviews, especially patients whose medicines for health conditions are made worse by smoking or who have a smoking related illness. Pharmacist and pharmacy staff can identify patients requesting OTC treatments or advice for NRT.
2	1.2.93	27	29	With an increasing role of specialist and consultant pharmacists, pharmacists play a vital role on the management of chronic conditions such as COPD. It is important to remember that pharmacist are experts in medicines and therefore are not only able to support patients in managing COPD, but discussing inhaler techniques and devices that better support patient's condition. We would recommend alongside nurse specialist having a pharmacist specialist in a multidisciplinary team.
3	1.2.99	30	23	More pharmacies have become healthy living pharmacies and taken a prominent role in providing patients with diet and lifestyle advice. Healthy Living Pharmacies have health champions who can promote wellbeing and health improvement.
Insert extra rows as needed				

Checklist for submitting comments

- Use this comment form and submit it as a **Word document (not a PDF)**.
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include **page and line number (not section number)** of the text each comment is about.
- Combine all comments from your organisation into 1 response. **We cannot accept more than 1 response from each organisation.**
- **Do not paste other tables into this table** – type directly into the table.

Please return to: COPDupdate@nice.org.uk

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (update) (Dec 2018)



Consultation on draft guideline – deadline for comments 5pm on 6 August 2018 email: COPDupdate@nice.org.uk

- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms **do not include attachments** such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. Further information regarding our privacy information can be found at our [privacy notice](#) on our website.